Research programme: GABAA receptor modulators - Euthymics

Drug Profile

Research programme: GABAA receptor modulators - Euthymics

Latest Information Update: 07 Sep 2010

Price : $50

At a glance

  • Originator DOV Pharmaceutical
  • Developer Euthymics Bioscience
  • Class
  • Mechanism of Action GABA A receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • No development reported Anxiety disorders; Epilepsy; Insomnia

Most Recent Events

  • 22 Jul 2010 Euthymics Bioscience acquires DOV Pharmaceutical
  • 16 Nov 2007 Preclinical trials in Insomnia in USA (unspecified route)
  • 16 Nov 2007 Preclinical trials in Epilepsy in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top